Research
Hormonal
GLP-1 receptor agonism (liraglutide) sensitizes hypothalamic POMC neurons and ventral tegmental area (VTA) dopaminergic neurons to nicotine, increasing their excitability and contributing to weight loss.
GLP-1 drugs may work better for smokers because they make the brain's reward and hunger centers more responsive to nicotine. This interaction increases the activity of neurons that suppress appetite and burn energy.
GoodSupportsHIGH confidence
Co-application of liraglutide and nicotine increased POMC excitability and firing rate, signifying that liraglutide sensitizes POMC neurons to nicotine... upon co-application of liraglutide and nicotine, an increase in dopaminergic excitability, amplitude, and firing rate was observed relative to the monoagonist control applications, signifying that liraglutide sensitizes dopaminergic neurons to nicotine actions in the VTA
Why this rating
Strong mechanistic evidence using electrophysiology, calcium imaging, and transcriptomics in animal models.
Source
GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity
Sarah Falk et al. · Cell Reports · 2023
DOI 10.1016/j.celrep.2023.112466
mechanism_onlyCited 33×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Co-administration of the GLP-1 receptor agonist liraglutide and nicotine synergistically lowers body weight in obese mice by simultaneously reducing food intake and increasing energy expenditure.Good
- Liraglutide attenuates nicotine-induced dopamine release in the nucleus accumbens (NAc), potentially reducing the addictive properties of nicotine while maintaining weight loss benefits.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →